Get the Stockscreener App
0.629
42.95%
0.189
After Hours:
.57
-0.059
-9.38%
Tuhura Biosciences Inc stock is traded at $0.629, with a volume of 2.26M.
It is up +42.95% in the last 24 hours and down -13.34% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$0.44
Open:
$0.4279
24h Volume:
2.26M
Relative Volume:
3.06
Market Cap:
$35.52M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+17.55%
1M Performance:
-13.34%
6M Performance:
-75.99%
1Y Performance:
-85.90%
1-Day Range:
$0.4268
$0.645
1-Week Range:
$0.41
$0.75
52-Week Range:
$0.41
$4.77
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
0.629 | 24.85M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug By Investing.com - Investing.com South Africa
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - MEXC
TuHURA Receives FDA Orphan Drug Designation - intellectia.ai
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug - Investing.com
FDA grants orphan status to TuHURA melanoma therapy IFx-2.0 - stocktitan.net
Quarterly Earnings: What dividend growth rate does TuHURA Biosciences Inc offer2025 Volume Leaders & Trade Opportunity Analysis - baoquankhu1.vn
TuHURA Biosciences Receives Nasdaq Minimum Bid Price Notice - TipRanks
TuHURA Biosciences Received Notice of Noncompliance - TradingView
Will TuHURA Biosciences Inc. outperform its industry peers2025 Volume Leaders & Safe Capital Investment Plans - mfd.ru
Risk Recap: How is TuHURA Biosciences Inc managing supply chain issuesJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Breakout Watch: How is TuHURA Biosciences Inc managing supply chain issuesWeekly Profit Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
TuHURA Biosciences (NASDAQ:HURA) Shares Up 0.5% – Here’s Why - Defense World
MACD Signal: Will TuHURA Biosciences Inc outperform its industry peers2025 Historical Comparison & Verified High Yield Trade Plans - baoquankhu1.vn
Will TuHURA Biosciences Inc. stock gain from lower inflation2025 Investor Takeaways & Expert Curated Trade Setup Alerts - Улправда
Will TuHURA Biosciences Inc. stock benefit from green energy trendsQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
Is TuHURA Biosciences Inc. stock supported by innovation pipelinePrice Action & Verified Momentum Stock Alerts - ulpravda.ru
HURA: Analyst Reiterates Buy Rating, Lowers Price Target | HURA Stock News - GuruFocus
Risk Hedge: Will TuHURA Biosciences Inc. (PL3) stock attract long term capital inflows - Улправда
Can TuHURA Biosciences Inc. (PL3) stock expand revenue streams2025 Historical Comparison & Weekly High Return Stock Forecasts - ulpravda.ru
Why TuHURA Biosciences Inc. stock is popular among millennialsTake Profit & AI Driven Stock Price Forecasts - ulpravda.ru
Why TuHURA Biosciences Inc. stock could see breakout soonMid Cap Growth Trends & Rapid Capital Gain - ulpravda.ru
TuHURA Biosciences Inc Stock Analysis and ForecastRetail Trading Trends & Enter Your Email to Get Stock Alerts - earlytimes.in
Tuhura Biosciences amends loan agreement, secures full $3M - MSN
Is TuHURA Biosciences Inc PL3 a good long term investmentStop Loss Placement Tips & Big Profit Small Investment - earlytimes.in
What the Latest News Means for ABS Marine Services Limited Stock InvestorsTake Profit Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
TUHURA Biosciences announces $15.6M registered direct offering - MSN
What analysts say about TuHURA Biosciences Inc PL3 stockEvening Star Patterns & Don’t Miss These Undervalued Stocks - earlytimes.in
Analysts Offer Insights on Healthcare Companies: Actinogen Medical (OtherATGGF) and TuHURA Biosciences (HURA) - The Globe and Mail
Does TuHURA Biosciences Inc. stock trade at a discount to peers2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - Улправда
Will TuHURA Biosciences Inc. (PL3) stock attract long term capital inflows2025 Technical Patterns & Expert Verified Movement Alerts - Улправда
Volume Summary: Does TuHURA Biosciences Inc. stock trade at a discount to peers2025 Trade Ideas & Free Safe Capital Growth Stock Tips - Улправда
Can TuHURA Biosciences Inc. stock reach $100 price targetPortfolio Update Summary & High Accuracy Trade Signal Alerts - Улправда
Aug Retail: How TuHURA Biosciences Inc. stock compares to industry benchmarksWeekly Profit Recap & Consistent Return Strategy Ideas - Улправда
2026 world cup match preview insights: Will TuHURA Biosciences Inc. stock outperform Nasdaq index2026 world cup usa national team round of 32 key players transition play match prediction guide - ulpravda.ru
How TuHURA Biosciences Inc. stock compares to industry benchmarksTrade Ideas & Consistent Growth Equity Picks - Улправда
Will TuHURA Biosciences Inc. stock deliver shareholder valueTrade Volume Report & Free Expert Approved Momentum Trade Ideas - Улправда
Is TuHURA Biosciences Inc. (PL3) stock a top pick for value investors2025 Trading Recap & Stepwise Trade Signal Implementation - Улправда
Can TuHURA Biosciences Inc. stock sustain free cash flow growth2025 Stock Rankings & Weekly High Potential Stock Alerts - DonanımHaber
Can TuHURA Biosciences Inc. stock weather global recessionWeekly Loss Report & Growth Focused Stock Reports - Улправда
TuHURA Biosciences Earnings Notes - Trefis
Rate Hike: Can TuHURA Biosciences Inc. (PL3) stock expand revenue streamsCEO Change & Weekly Top Gainers Alerts - Улправда
[Form 4] TuHURA Biosciences, Inc./NV Insider Trading Activity - Stock Titan
TuHURA Biosciences, Inc. (HURA) CEO discloses 3.4M option grant terms in filing - Stock Titan
TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
TuHURA Biosciences Announces Its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone - 富途牛牛
TuHURA Biosciences announces release of Kintara’s CVR - TipRanks
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):